Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment

Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment

Nephrotic syndrome affects about 2–7 per 100,000 children yearly and accounts for less than 15% of end stage kidney disease. Steroids still represent the cornerstone of therapy achieving remission in 75–90% of the cases The remaining part result as steroid resistant nephrotic syndrome, characterized...

Full description

Bibliographic Details
Main Authors: Andrea Angeletti, Maurizio Bruschi, Xhuliana Kajana, Edoardo La Porta, Sonia Spinelli, Gianluca Caridi, Francesca Lugani, Enrico Eugenio Verrina, Gian Marco Ghiggeri
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
nephrotic syndrome
rituximab
daratumumab
CD38
CD20
focal segmental glomerulosclerosis
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213203/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1213203/full

Similar Items